Continuous glucose monitoring in stroke patients with diabetes

Continuous glucose monitoring for enhanced hyperglycemia management in type 2 diabetes patients undergoing endovascular therapy for acute ischemic stroke - the impact of CGM for enhanced detection and management of hyperglycemia in persons with acute ischemic stroke

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON58365

Enrollment

Registered

2025-03-13

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke, type 2 diabetes mellitus stroke and diabetes

Interventions

CGM Freestyle Libre 2

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients =18 years with acute ischemic stroke; diagnosed with type 2 diabetes mellitus; treatment with EVT <24h after symptom onset

Exclusion criteria

Exclusion criteria: Hypotension, dialysis or eGFR < 15; drugs interfering with CGM accuracy; skin infection at sensor site; pregnancy; relevant pancreatic disease; systemic corticosteroids > 5 mg; expected ICU admission.

Design outcomes

Primary

Measure	Time frame
Percentage of time with glucose levels above 10 mmol/L (time above range), as measured by the CGM.	—

Secondary

Measure	Time frame
Secondary outcomes include other glucose parameters, in-hospital complications, and functional and neurological outcomes.	—

Countries

Netherlands

Contacts

Public ContactJ. J. Bakker

Isala

onderzoek@isala.nl0886248187

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 22, 2026